Recovery characteristics of patients receiving either sugammadex or neostigmine and glycopyrrolate for reversal of neuromuscular block: a randomised controlled trial

• Published in: Anaesthesia 2018-03, Vol.73 (3), p.340-347
• Main Authors: Paech, M. J., Kaye, R., Baber, C., Nathan, E. A.
• Format: Article
• Language: English
• Subjects: Anesthesia; Evidence-based medicine; Glycopyrrolate; Gynecological surgery; Incidence; Laparoscopy; Motivation; Nausea; Neostigmine; neuromuscular block reversal: assessment; neuromuscular block: rocuronium, neostigmine, sugammadex; Neuromuscular system; postoperative nausea and vomiting (PONV): prophylaxis; Randomization; Recovery (Medical); Surgery; Vomiting
• ISSN: 0003-2409; 1365-2044
• DOI: 10.1111/anae.14174

Summary Sugammadex more rapidly and reliably reverses rocuronium‐induced neuromuscular block compared with neostigmine, but it is not known if subsequent patient outcomes, including nausea, vomiting and other aspects of recovery are modified. In this study, we compared the recovery characteristics of sugammadex and neostigmine/glycopyrrolate following reversal of neuromuscular block. This was a single‐centre, randomised, blinded, parallel‐group clinical trial in women undergoing elective day‐surgical laparoscopic gynaecological surgery, with a standardised general anaesthesia regimen that included rocuronium. Neuromuscular block was reversed with either sugammadex 2 mg.kg−1 or neostigmine 40 μg.kg−1 and glycopyrrolate 400 μg. The primary outcome was the incidence of nausea and vomiting during the first six postoperative hours. Secondary outcomes included other measures of postoperative recovery such as patient symptoms and recovery scores. Three‐hundred and four women were analysed by intention‐to‐treat (sugammadex n = 151, neostigmine n = 153), which included four major protocol violations. There was no significant difference between sugammadex and neostigmine groups in the incidence of early nausea and vomiting (49.0% vs. 51.0%, respectively; OR 0.92, 95%CI 0.59–1.45; p = 0.731). Double vision (11.5% vs. 20.0%; p = 0.044) and dry mouth (71.6% vs. 85.5%; p = 0.003) were less common after sugammadex. Sedation scores at 2 h were also lower after sugammadex (median (IQR [range]) 0 (0‐3 [0‐10]) vs. 2 (0‐4.[0‐10]); p = 0.021). Twenty‐four‐hour recovery scores were not significantly different between groups. Reversal with sugammadex in this patient population did not reduce postoperative nausea or vomiting compared with neostigmine/glycopyrrolate.